Page 56 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat
P. 56

Liver stiffness and fibrosis-4 score at sustained virological response in hepatoma
               risk assessment for chronic hepatitis C patients after direct-acting antivirals



                 Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Chien-Hung Chen, Tsung-Hui Hu,
                                                     Sheng-Nan Lu
                          Division of Hepato-Gastroenterology, Department of Internal Medicine

             Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan


            OBJECTIVES: Chronic hepatitis C (CHC) patients after direct antiviral agents remained at risk of
            hepatocellular carcinoma (HCC). This study was to determine whether liver stiffness (LS) and

            fibrosis-4 score (FIB-4) were useful in assessing HCC risk for CHC patients after direct-acting
            antivirals (DAA).
            METHODS: This retrospective study enrolled CHC patients achieving SVR after DAA. Those with
            LS measurement and complete lab data at SVR were followed and analyzed. The demographics,

            clinical characteristics and HCC development were obtained from medical chart reviews. The
            diagnosis of HCC was based on recommended criteria.
            RESULTS: A total of 703 (M/F: 296/407, mean age: 63.8 year) patients were enrolled. The median
            follow-up period was 2.24 years. Twenty-eight patients (M/F:13/15, mean age: 65.6 years) developed

            HCC. The 3-year cumulative HCC incidence was 5.8 %. The performance of LS and FIB-4 in
            predicting HCC occurrence as assessed by area under receiver operating curve was 0.775 and 0.739.
            The optimal cutoff was 11kPa and 3.6 for LS and FIB-4, obtained with Youden’s index. Multivariate
            analysis showed LS>=11kPa (hazard ratio:2.695, 95% confidence interval: 1.069-6.792, p=0.036)

            and FIB-4 >=3.6 (3.068, 1.352-6.962, p=0.007) were independently associated with HCC
            development. The 3-year cumulative rate of HCC development was 18.2% for patients with
            LS>=11kPa and FIB-4>=3.6, while it was 2.5% for those without (log-rank p-value: <0.001).
            CONCLUSIONS: For CHC patients achieving SVR after DAA, LS and FIB-4 was useful in HCC

            risk assessment. Patients with both LS>=11kPa and FIB-4>=3.6 at SVR had the highest risk of HCC
            development.
   51   52   53   54   55   56   57   58   59   60   61